Zanolimumab, with the CAS number 652153-01-0, is a monoclonal antibody that primarily targets the CD4 receptor on T cells. It is designed to modulate immune responses, making it a candidate for therapeutic applications in autoimmune diseases and certain types of cancer. As a humanized IgG1 antibody, Zanolimumab exhibits high specificity and affinity for its target, which helps in reducing the risk of immunogenicity compared to fully murine antibodies. The mechanism of action involves blocking the interaction between CD4 and MHC class II molecules, thereby inhibiting T cell activation and proliferation. This characteristic makes it a potential treatment option for conditions characterized by excessive T cell activity. Zanolimumab has undergone various clinical trials to evaluate its efficacy and safety profile, particularly in the context of diseases such as rheumatoid arthritis and psoriasis. Its development reflects ongoing efforts in biopharmaceuticals to harness the immune system for therapeutic benefit while minimizing adverse effects.

Zanolimumab

652153-01-0: Zanolimumab, with the CAS number 652153-01-0, is a monoclonal antibody that primarily targets the CD4 receptor on T cells. It is designed to modulate immune responses, making it a candidate for therapeutic applications in autoimmune diseases and certain types of cancer. As a humanized IgG1 antibody, Zanolimumab exhibits high specificity and affinity for its target, which helps in reducing the risk of immunogenicity compared to fully murine antibodies. The mechanism of action involves blocking the interaction between CD4 and MHC class II molecules, thereby inhibiting T cell activation and proliferation. This characteristic makes it a potential treatment option for conditions characterized by excessive T cell activity. Zanolimumab has undergone various clinical trials to evaluate its efficacy and safety profile, particularly in the context of diseases such as rheumatoid arthritis and psoriasis. Its development reflects ongoing efforts in biopharmaceuticals to harness the immune system for therapeutic benefit while minimizing adverse effects.

<p>Anti-CD4 human monoclonal antibody</p>

<p>Zanolimumab is a humanised monoclonal antibody targeting CD4, blocking TCR signalling, autoimmune diseases such as rheumatoid arthritisa.</p>

CAS 652153-01-0

Zanolimumab

Zanolimumab

Ref: 3D-CLA1164

Zanolimumab

Ref: TM-T80744